| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents, end of year | 6,365,624 | 8,705,218 | 8,662,091 | 9,669,546 |
| Prepaid insurance | 218,810 | NaN | NaN | NaN |
| Amount of contract research organizations | 390,000 | NaN | NaN | NaN |
| Amount of prepaid professional services | 298,525 | NaN | NaN | NaN |
| Amount of prepaid services | 9,621 | NaN | NaN | NaN |
| Prepaid expense, current | 916,956 | 1,086,121 | 1,119,321 | 1,327,185 |
| Deferred financing costs | 0 | 99,305 | NaN | NaN |
| Total current assets | 7,282,580 | 9,890,644 | 9,781,412 | 10,996,731 |
| Operating lease, right-of-use asset | 144,331 | 170,733 | 196,249 | 220,999 |
| Deferred costs, noncurrent | NaN | NaN | NaN | 716,898 |
| Assets | 7,426,911 | 10,061,377 | 9,977,661 | 11,934,628 |
| Accounts payable, current | 2,278,619 | 3,435,297 | 2,027,509 | 1,770,178 |
| Accrued and other accounts payable | 1,038,731 | 995,290 | 1,560,430 | 1,828,312 |
| Represents the related party payable | 147,223 | 116,476 | 143,080 | 121,273 |
| Operating lease, liability, current | 145,456 | 145,456 | 141,070 | 124,402 |
| Net balance as at december 31, 2025 | 2,343,778 | 5,245,543 | 6,785,812 | 4,700,000 |
| Liabilities, current | 5,953,807 | 9,938,062 | 10,657,901 | 8,544,165 |
| Loans payable, noncurrent | 21,042 | 25,865 | 29,462 | NaN |
| Operating lease, liability, noncurrent | 24,168 | 60,139 | 95,188 | 141,753 |
| Total liabilities | 5,999,017 | 10,024,066 | 10,782,551 | 8,685,918 |
| Common stock, value, issued | 67,114,012 | 57,076,175 | 4 | 37,833,999 |
| Represents the amount of common shares to be issued | 313,934 | 313,934 | 313,934 | NaN |
| Additional paid-in capital | 7,478,881 | 6,879,575 | 6,449,863 | 5,597,106 |
| Accumulated other comprehensive income (loss), net of tax | -190,510 | 10,880 | 10,676 | NaN |
| Accumulated deficit | -73,390,261 | -64,348,118 | -5 | -40,182,395 |
| Equity, attributable to parent | 1,326,056 | -67,554 | -910,126 | NaN |
| Equity, attributable to noncontrolling interest | 101,838 | 104,865 | 105,236 | NaN |
| Ending balance | 1,427,894 | 37,311 | -804,890 | 3,248,710 |
| Total liabilities and shareholders' deficit | 7,426,911 | 10,061,377 | 9,977,661 | 11,934,628 |
Medicus Pharma Ltd. (MDCXW)
Medicus Pharma Ltd. (MDCXW)